Aveo Receives Milestone Payment From Biogen

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, Wednesday announced it has received a $5 million milestone payment from Biogen Idec International GmbH … for the selection of the first humanized antibody development candidate from its ErbB3 program.
Forbes